426 related articles for article (PubMed ID: 19017726)
1. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
2. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
3. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
4. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
[TBL] [Abstract][Full Text] [Related]
5. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
[TBL] [Abstract][Full Text] [Related]
6. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
[TBL] [Abstract][Full Text] [Related]
7. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
[TBL] [Abstract][Full Text] [Related]
8. biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
Gumlaw N; Sevigny LM; Zhao H; Luo Z; Bangari DS; Masterjohn E; Chen Y; McDonald B; Magnay M; Travaline T; Yoshida-Moriguchi T; Fan W; Reczek D; Stefano JE; Qiu H; Beil C; Lange C; Rao E; Lukason M; Barry E; Brondyk WH; Zhu Y; Cheng SH
Mol Ther; 2020 Feb; 28(2):664-676. PubMed ID: 31843448
[TBL] [Abstract][Full Text] [Related]
9. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
[TBL] [Abstract][Full Text] [Related]
10. Abnormal glycosylation of dystroglycan in human genetic disease.
Hewitt JE
Biochim Biophys Acta; 2009 Sep; 1792(9):853-61. PubMed ID: 19539754
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.
Yu M; He Y; Wang K; Zhang P; Zhang S; Hu H
Hum Gene Ther; 2013 Mar; 24(3):317-30. PubMed ID: 23379513
[TBL] [Abstract][Full Text] [Related]
12. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
[TBL] [Abstract][Full Text] [Related]
14. [Recent Advances in α-dystroglycanopathy].
Kuga A; Kanagawa M; Toda T
Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
[TBL] [Abstract][Full Text] [Related]
15. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.
Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY
EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.
Longman C; Brockington M; Torelli S; Jimenez-Mallebrera C; Kennedy C; Khalil N; Feng L; Saran RK; Voit T; Merlini L; Sewry CA; Brown SC; Muntoni F
Hum Mol Genet; 2003 Nov; 12(21):2853-61. PubMed ID: 12966029
[TBL] [Abstract][Full Text] [Related]
17. Zebrafish models for human FKRP muscular dystrophies.
Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
[TBL] [Abstract][Full Text] [Related]
18. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
[TBL] [Abstract][Full Text] [Related]
19. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
[TBL] [Abstract][Full Text] [Related]
20. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
